title: What is new in the management of rapidly progressive glomerulonephritis?
abstract: Rapidly progressive glomerulonephritis (RPGN) results from severe crescentic damage to glomeruli and leads to irreversible kidney failure if not diagnosed and managed in a timely fashion. Traditional treatment has relied on glucocorticoids and cyclophosphamide, with additional plasmapheresis for certain conditions. Here we describe updates in the management of RPGN, according to the underlying renal pathology. However, there remains a paucity of trials that have enrolled patients with more advanced renal disease, dialysis dependence or with RPGN, and we are therefore still reliant on extrapolation of data from studies of patients with a less severe form of disease. In addition, reporting bias results in publication of cases or cohorts showing benefit for newer agents in advanced disease or RPGN, but it remains unclear how many unsuccessful outcomes in these circumstances take place. Since clinical trials specifically in RPGN are unlikely, use of biologic registries or combination of sufficient sized cohort series may provide indications of benefit outside of a clinical trial setting and should be encouraged, in order to provide some evidence for the efficacy of therapeutic regimens in RPGN and advanced renal disease.
authors: UCL Centre for Nephrology , Royal Free Hospital , London , UK.
authors: George H B
authors: GH
authors: Greenhall
authors: UCL Centre for Nephrology , Royal Free Hospital , London , UK.
authors: Alan D
authors: AD
authors: Salama
keywords: AKI; IgA nephropathy; glomerulonephritis; systemic lupus erythematosus; vasculitis